Compare · ARGX vs BCAB
ARGX vs BCAB
Side-by-side comparison of argenx SE (ARGX) and BioAtla Inc. (BCAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and BCAB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 18169.4x BCAB ($2.9M).
- ARGX has been more active in the news (6 items in the past 4 weeks vs 1 for BCAB).
- ARGX has more recent analyst coverage (25 ratings vs 8 for BCAB).
- Company
- argenx SE
- BioAtla Inc.
- Price
- -
- -
- Market cap
- $52.52B
- $2.9M
- 1M return
- -
- +0.00%
- 1Y return
- -
- -95.63%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 6
- 1
- Recent ratings
- 25
- 8
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
BioAtla Inc.
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest BCAB
- BioAtla Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Medical Officer Sievers Eric covered exercise/tax liability with 134 shares, decreasing direct ownership by 1% to 11,346 units (SEC Form 4)
- Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 259 shares, decreasing direct ownership by 0.50% to 52,035 units (SEC Form 4)
- Chief Financial Officer Vasquez Christian covered exercise/tax liability with 71 shares, decreasing direct ownership by 0.67% to 10,476 units (SEC Form 4)
- BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by BioAtla Inc.
- BioAtla Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Financial Officer Vasquez Christian covered exercise/tax liability with 257 shares, decreasing direct ownership by 2% to 10,347 units (SEC Form 4)
- Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 898 shares, decreasing direct ownership by 2% to 52,294 units (SEC Form 4)
- Chief Medical Officer Sievers Eric covered exercise/tax liability with 494 shares, decreasing direct ownership by 1% to 11,840 units (SEC Form 4)